Articles dans des revues avec comité de lecture (179)
  1. 119. Lemaire, A., Trepo, E., Ouziel, R., Gustot, T., Moreno, C., Degré, D., Minsart, C., Quertinmont, E., Vercruysse, V., De Wilde, V., Le Moine, O., Devière, J., Abramowicz, M., Le Moine, A., & Lemmers, A. (2013). Microsatellite polymorphism in the heme oxygenase-1 gene promoter is not associated with alcoholic liver disease severity. Hepatology, 59(1), 352-353. doi:10.1002/hep.26534
  2. 120. Trepo, E., Ouziel, R., Pradat, P., Momozawa, Y., Quertinmont, E., Gervy, C., Gustot, T., Degré, D., Vercruysse, V., Deltenre, P., Verset, L., Gulbis, B., Franchimont, D., Devière, J., Lemmers, A., & Moreno, C. (2013). Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. Journal of hepatology, 59(2), 344-350. doi:10.1016/j.jhep.2013.03.024
  3. 121. Lenz, O., Vijgen, L., Berke, J. M., Cummings, M. D., Fevery, B., Peeters, M. P., De Smedt, G., Moreno, C., & Picchio, G. (2013). Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). Journal of hepatology, 58(3), 445-451. doi:10.1016/j.jhep.2012.10.028
  4. 122. Nevens, F., Colle, I., Michielsen, P., Robaeys, G., Moreno, C., Caekelbergh, K., Lamotte, M., & Wyffels, V. (2012). Resource use and cost of hepatitis C-related care. European journal of gastroenterology & hepatology, 24(10), 1191-1198. doi:10.1097/MEG.0b013e3283566658
  5. 123. Deuffic-Burban, S., Deltenre, P., Buti, M., Stroffolini, T., Parkes, J., Mühlberger, N., Siebert, U., Moreno, C., Hatzakis, A., Rosenberg, W., Zeuzem, S., & Mathurin, P. (2012). Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology, 143(4), 974-85.e14. doi:10.1053/j.gastro.2012.05.054
  6. 124. Degré, D., Lemmers, A., Gustot, T., Ouziel, R., Trepo, E., Demetter, P., Verset, L., Quertinmont, E., Vercruysse, V., Le Moine, O., Devière, J., & Moreno, C. (2012). Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutrophil infiltrates. Clinical and experimental immunology, 169(3), 302-310. doi:10.1111/j.1365-2249.2012.04609.x
  7. 125. Moreno, C., & Deltenre, P. (2012). Prise en charge de l'hépatite C chronique en 2012 en Belgique. Revue médicale de Bruxelles, 33(4), 223-227.
  8. 126. Lucidi, V., Katsanos, G., Buggenhout, A., Moreno, C., Gustot, T., Boon, N., Degré, D., Bourgeois, N., Brisbois, D., Bali, M. A., Demetter, P., Van Laethem, J.-L., & Donckier De Donceel, V. (2012). Traitement du carcinome hépato-cellulaire chez le patient cirrhotique: la nécessité d'une approche pluridisciplinaire. Revue médicale de Bruxelles, 33(4), 229-236.
  9. 127. Gustot, T., & Moreno, C. (2012). Prise en charge de l'hépatite alcoolique aiguë. Revue médicale de Bruxelles, 33(4), 212-214.
  10. 128. Schreiber, J., Moreno, C., Garcia, B., Louvet, A., Trepo, E., Henrion, J., Thabut, D., Mathurin, P., & Deltenre, P. (2012). Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Alimentary pharmacology & therapeutics, 36(4), 353-362. doi:10.1111/j.1365-2036.2012.05197.x
  11. 129. Afdhal, N., Giannini, E. G., Tayyab, G., Mohsin, A., Lee, J.-W., Andriulli, A., Jeffers, L., McHutchison, J. G., Chen, P.-J., Han, K.-H., Campbell, F., Hyde, D., Brainsky, A., Theodore, D., & Moreno, C. (2012). Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. The New England journal of medicine, 367(8), 716-724. doi:10.1056/NEJMoa1110709
  12. 130. Moreno, C., Berg, T., Tanwandee, T., Thongsawat, S., Van Vlierberghe, H., Zeuzem, S., Lenz, O., Peeters, M. P., Sekar, V., & De Smedt, G. (2012). Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. Journal of hepatology, 56(6), 1247-1253. doi:10.1016/j.jhep.2011.12.033
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Suivant >>